Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
Instil's licensed PD-L1xVEGF bispecific shows promise in China
Tumors diminished in 62% of patients with advanced non-small cell lung cancer given IMM2510, instilling hope for an upcoming U.S. trial.
Darren Incorvaia
Jul 31, 2025 2:10pm
Royalty signs off $2B to bankroll Revolution's RAS cancer drug
Jun 24, 2025 9:00am
Nuvalent trots out strong pivotal data in FDA lung cancer push
Jun 24, 2025 6:30am
ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC
May 22, 2025 5:00pm
Roche nets FDA breakthrough label for AI lung cancer CDx test
Apr 29, 2025 2:07pm
BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects
Apr 3, 2025 8:05am
